Cell Therapeutics, Inc. Announces Filing of Form 10-K

SEATTLE, March 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)
(Nasdaq and MTA: CTIC) today announced that the filing of its annual report on
Form 10-K for the year ended December 31, 2007 has now been timely completed.
This filing is available for review on CTI's Web site at
http://www.CellTherapeutics.com or on the Securities and Exchange Commission's
Web site at http://www.sec.gov.
As required under Nasdaq Marketplace Rule 4350(b)(1)(B), CTI also
announced that its independent auditor's report included in the annual report
on Form 10-K contains a "going concern" qualification.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to
developing an integrated portfolio of oncology products aimed at making cancer
more treatable. For additional information, please visit
http://www.CellTherapeutics.com.
Media Contact:
Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: media@ctiseattle.com
http://www.CellTherapeutics.com/media.htm

Investors Contact:
Leah Grant
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
http://www.CellTherapeutics.com/investors.htm

SOURCE Cell Therapeutics, Inc.

media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
media@ctiseattle.com, or investors, Leah Grant, +1-206-282-7100, fax,
+1-206-272-4434, invest@ctiseattle.com, both of Cell Therapeutics, Inc.